Biocon Limited has informed the Exchange regarding a press release dated May 08, 2025, titled "Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA atRs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% FY25 Revenue at Rs 16,470 Cr; EBITDA at Rs 4,374Cr; Net Profit at Rs 1,013 Cr".

Profit growth above 25%Exceptional itemEBITDA margin expansionResults View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹333.50

prior close

₹333.50

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.0%-0.8% vs market

Pharmaceuticals peers, median of 146sector-0.2%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+1.3

15m

+1.2

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+0.0-0.8-0.2-0.6

Next day

-1.6+3.8-5.4+2.5-4.1

-1.0+4.0-5.0+4.0-5.0

+1.4+5.3-3.9+4.4-3.0

+1.3+6.1-4.8+5.1-3.8

+1.6+7.0-5.4+5.5-3.8

-0.1+5.5-5.6+5.5-5.6

15d

+0.3+7.8-7.5+7.3-7.1

+1.3+11.8-10.6+7.9-6.6

+12.2+11.7+0.6+8.7+3.5

+2.4+7.1-4.7+3.1-0.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon reported Q4FY25 consolidated revenue of Rs 4,454 crore, up 12% year-on-year (15% on a like-for-like basis after adjusting for the Branded Formulations India divestment). Q4 EBITDA rose 16% to Rs 1,115 crore with margins of 25%, and net profit jumped 153% to Rs 344 crore, helped by a low base. For the full year FY25, revenue grew 5% to Rs 16,470 crore (8% like-for-like), EBITDA was up 5% at Rs 4,374 crore with margins steady at 27%, and net profit was nearly flat at Rs 1,013 crore (up 30% on a like-for-like basis). The Generics business led growth with a 46% jump in Q4, while Biosimilars grew 9% like-for-like and Syngene rose 11%. The Board has recommended a final dividend of Rs 0.50 per share and approved a fund-raising plan of up to Rs 4,500 crore via QIP, rights issue or other routes, mainly to repay or restructure borrowings. A committee has also been set up to evaluate a potential merger of Biocon Biologics with Biocon Limited.

Likely market impact

Strong quarterly earnings, especially in Generics and Biosimilars, should support sentiment, while the proposed Rs 4,500 crore capital raise and possible BBL-BL merger could cause near-term dilution and structural overhang. The small final dividend and flat reported FY25 net profit offer limited cash returns for shareholders.

By the numbersConsolidated · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹4,417 Cr	₹3,917 Cr	+12.8%
Operating profit	₹429.5 Cr	₹281.9 Cr	+52.4%
Profit after tax	₹459.4 Cr	₹222.9 Cr	+106.1%
EBITDA margin	24.9%	23.2%	+1.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.